MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.
- Registration Number
- NCT05255471
- Lead Sponsor
- National Cancer Institute, Naples
- Brief Summary
MITO 35b is designed as randomized, open label, phase III trial that aims to assess the efficacy of olaparib maintenance beyond progression compered to standard platinum-based chemotherapy after secondary cytoreductive surgery.
The target population of this study are ovarian cancer patients who experience a disease recurrence or progression to a first line maintenance therapy with PARPi; at progression patients must have received a secondary cytoreduction according to clinical practice.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 200
Not provided
-
Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease, and/or active, uncontrolled infection. that may interfere with planned treatment, affect patient compliance or place the patient at high risk from treatment related complications [Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, New York Heart Association (NYHA) grade II or greater congestive heart failure, uncontrolled hypertension, severe peripheral vascular disease, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric illness ];
-
Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication;
-
Patients eligible for a platinum based chemotherapy doublet and bevacizumab;
-
Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatments; prior palliative radiation must have been completed at least 7 days prior to the start of study drugs, and patients must have recovered from any acute adverse effects prior to the start of study treatment;
-
Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of major surgery;
-
Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT);
-
Breast feeding women;
-
Patients with symptomatic uncontrolled brain metastases. A TC/RMN scan of brain is required at baseline. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days;
-
Other malignancy unless curatively treated with no evidence of disease for ≥5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS) and Stage 1, grade 1 endometrial carcinoma;
-
Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable) except for transfusion done during surgery;
-
Persistent toxicities >grade 2 according Common Terminology Criteria for Adverse (CTCAE) version 5.0 caused by previous cancer therapy, excluding alopecia;
-
Resting ECG indicating uncontrolled, potentially irreversible cardiac conditions, as judged by the investigator (eg., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation > 470 ms, electrolyte disturbances, etc.), or patients with congenital long QT syndrome;
-
Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks;
-
Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents;
-
Patients with myelodysplastic syndrome (MSD)/acute myeloid leukaemia (AML) or with features suggestive of MDS/AML;
-
Immunocompromised patients, e.g., patients who are known to be serologically positive (HIV 1-2 antibody positivity) for human immunodeficiency virus (HIV);
-
Patients with a known hypersensitivity to olaparib or any of the excipients of the product;
-
Patients that, at the Investigator's opinion, are not eligible according to ESMO (European society for Medical Oncology) guidelines for a re-treatment with a platinum containing therapy (i.e. patient has experienced a major adverse reaction to platinum salts during first line therapy);
-
Patients with known active hepatitis (i.e. Hepatitis B or C)
- Active hepatitis B virus (HBV) is defined by a known positive HBV surface antigen (HBsAg) result. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody and absence of HBsAg) are eligible.
- Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
-
Participation in another clinical study with an investigational product during the last 3 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Olaparib Olaparib - Chemotherapy Chemotherapy drug -
- Primary Outcome Measures
Name Time Method Progression-free survival (PFS) until progression disease ( up to 5 years ) PFS as defined by the Investigator using RECIST 1.1, as the time frame from randomization to progression or death for any cause,whichever comes first
Progession free survival 2 (PFS2) until progression disease ( up to 5 years ) PFS as defined by the Investigator using RECIST 1.1, as the time frame from randomization to second progression or death for any cause
- Secondary Outcome Measures
Name Time Method Determination of changes in quality of life At baseline, at Day 1 of each Cycle (during treatment) until 6 months, then at 9 and 12 months (up to 12 months).Each cycle is 28 days EORTC QLQ-C30, a quality questionnaire, composed by 30 items graded from 1 (not at all) to 4 (very much).
Determination of changes in patient-reported outcome (PRO) symptomatic toxicities At baseline, at Day 1 of each Cycle (during treatment) until 6 months, then at 9 and 12 months (up to 12 months. Each cycle is 28 days PRO-CTCAE questionnaire, composed by 78 items graded from 1 (not at all) to 5 (very much).
Overall survival 5 years OS as defined by the Investigator as the time from randomization to death for any cause, whichever comes first.
Changes in patient-reported outcome (PRO) of cancer-related financial toxicity t baseline, at day 1 of each Cycle (during treatment) until 6 months, then at 9 and 12 months (up to 12 months). Each cycle is 28 days The PROFFITquestionnaire consists of 16 items,graded from 1 (not at all) to 4 (very much).
Number of participants with treatment-related side effects At baseline, day 1 of each cycle until progression disease (up to 5 years)].Each cycle is 28 days. Number of participants with treatment-related side effects
Number of participants with treatment-related side effects graded according to Common Criteria for Adverse Events (CTCAE) version 5.0
Trial Locations
- Locations (1)
IRCCS Istituto Nazionale Tumori di Napoli
🇮🇹Naples, Italy